In vitro and in vivo biological activity of PEDF against a range of tumors

Expert Opinion on Therapeutic Targets

Volumn 13, Issue 12, 2009, Pages 1429-1438

  Broadhead, Matthew L ^a   Dass, Crispin R ^a   Choong, Peter Fm ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

angiogenesis; cancer; PEDF; therapy; tumor

Indexed keywords

CANCER GROWTH FACTOR; FOCAL ADHESION KINASE; GELATINASE B; PLACENTAL GROWTH FACTOR; PROTEIN BCL 2; PROTEIN P53; RECOMBINANT GROWTH FACTOR; RECOMBINANT PIGMENT EPITHELIUM DERIVED FACTOR; THROMBOSPONDIN 1; UNCLASSIFIED DRUG; UROKINASE; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; EYE PROTEIN; NERVE GROWTH FACTOR; PIGMENT EPITHELIUM DERIVED FACTOR; PIGMENT EPITHELIUM-DERIVED FACTOR; SERINE PROTEINASE INHIBITOR;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CANCER LOCALIZATION; CANCER SIZE; CANCER THERAPY; CELL PROLIFERATION; COLONY FORMATION; DISEASE COURSE; GLIOBLASTOMA; HUMAN; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LUNG CARCINOMA; MELANOMA; NICK END LABELING; NONHUMAN; OSTEOSARCOMA; OSTEOSARCOMA CELL; OVARY CARCINOMA; PANCREAS ADENOCARCINOMA; PROSTATE CARCINOMA; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; UMBILICAL VEIN ENDOTHELIAL CELL; WESTERN BLOTTING; ANIMAL; FEMALE; MALE; NEOPLASM; PHYSIOLOGY;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; EYE PROTEINS; FEMALE; HUMANS; MALE; NEOPLASMS; NERVE GROWTH FACTORS; SERPINS;

EID: 75349111879     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728220903307475     Document Type: Review

References (49)

1. Becerra SP. Focus on molecules: pigment epithelium-derived factor (PEDF). Exp Eye Res 2006;82(5):739-40
2. Tombran-Tink J, Johnson LV. Neuronal differentiation of retinoblastoma cells induced by medium conditioned by human RPE cells. Invest Ophthalmol Vis Sci 1989;30(8):1700-7 (Pubitemid 19214990)
3. Becerra SP. Structure-function studies on PEDF. A noninhibitory serpin with neurotrophic activity. Adv Exp Med Biol 1997;425:223-37 (Pubitemid 28035786)
4. Tombran-Tink J, Chader GG, Johnson LV. PEDF: a pigment epithelium-derived factor with potent neuronal differentiative activity. Exp Eye Res 1991;53(3):411-4
5. Ek ET, Dass CR, Choong PF. PEDF: a potential molecular therapeutic target with multiple anti-cancer activities. Trends Mol Med 2006;12(10):497-502 (Pubitemid 44468197)
6. Tombran-Tink J, Barnstable CJ. Therapeutic prospects for PEDF: more than a promising angiogenesis inhibitor. Trends Mol Med 2003;9(6):244-50 (Pubitemid 36841683)
7. Quan GM, Choong PF. Anti-angiogenic therapy for osteosarcoma. Cancer Metastasis Rev 2006;25(4):707-13 (Pubitemid 46071873)
8. Dawson DW, Volpert OV, Gillis P, et al. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 1999;285(5425):245-8 (Pubitemid 29329995)
9. Maik-Rachline G, Shaltiel S, Seger R. Extracellular phosphorylation converts pigment epithelium-derived factor from a neurotrophic to an antiangiogenic factor. Blood 2005;105(2):670-8 (Pubitemid 40070751)
10. Ren JG, Jie C, Talbot C. How PEDF prevents angiogenesis: a hypothesized pathway. Med Hypotheses 2005;64(1):74-8 (Pubitemid 39469238)
11. Becerra SP, Sagasti A, Spinella P, Notario V. Pigment epithelium-derived factor behaves like a noninhibitory serpin. Neurotrophic activity does not require the serpin reactive loop. J Biol Chem 1995;270(43):25992-9
12. Zhang L, Chen J, Ke Y, et al. Down-regulation of PEDF expression by ribozyme transgene in endothelial and lung cancer cells and its impact on angiogenesis in vitro. Oncol Rep 2005 2005;14(6):1615-9
13. Zhang LJ, Chen JF, Lu AP, et al. Expression of placental growth factor and pigment epithelium-derived factor in non-small cell lung cancer and the prognostic significance thereof. Zhonghua Yi Xue Za Zhi 2005;85(47):3328-31
14. Zhang L, Chen J, Ke Y, et al. Expression of pigment epithelial derived factor is reduced in non-small cell lung cancer and is linked to clinical outcome. Int J Mol Med 2006;17(5):937-44
15. Chen J, Ye L, Zhang L, Jiang WG. The molecular impact of pigment epithelium-derived factor, PEDF, on lung cancer cells and the clinical significance. Int J Oncol 2009;35(1):159-66
16. Chen JF, Zhao W, Zhang JZ, et al. Effects of pigment epithelial derived factor gene on growth of lung cancer cell and neovascularization: experiments with lung cancer cells and chick embryos. Zhonghua Yi Xue Za Zhi 2009;89(7):485-90
17. Cai J, Parr C, Watkins G, et al. Decreased pigment epithelium-derived factor expression in human breast cancer progression. Clin Cancer Res 2006;12(11 Pt 1):3510-7
18. Doll JA, Stellmach VM, Bouck NP, et al. Pigment epithelium-derived factor regulates the vasculature and mass of the prostate and pancreas. Nat Med 2003;9(6):774-80 (Pubitemid 36749229)
19. Filleur S, Volz K, Nelius T, et al. Two functional epitopes of pigment epithelial-derived factor block angiogenesis and induce differentiation in prostate cancer. Cancer Res 2005;65(12):5144-52 (Pubitemid 40827323)
20. Guan M, Jiang H, Xu C, et al. Adenovirus-mediated PEDF expression inhibits prostate cancer cell growth and results in augmented expression of PAI-2. Cancer Biol Ther 2007;6(3):419-25 (Pubitemid 47328311)
21. Halin S, Wikstrom P, Rudolfsson SH, et al. Decreased pigment epithelium-derived factor is associated with metastatic phenotype in human and rat prostate tumors. Cancer Res 2004;64(16):5664-71 (Pubitemid 39095563)
22. Cheung LW, Au SC, Cheung AN, et al. Pigment epithelium-derived factor is estrogen sensitive and inhibits the growth of human ovarian cancer and ovarian surface epithelial cells. Endocrinology 2006;147(9):4179-91 (Pubitemid 44268369)
23. Phillips NJ, Ziegler MR, Radford DM, et al. Allelic deletion on chromosome 17p13.3 in early ovarian cancer. Cancer Res 1996;56(3):606-11 (Pubitemid 26043661)
24. Uehara H, Miyamoto M, Kato K, et al. Expression of pigment epithelium-derived factor decreases liver metastasis and correlates with favorable prognosis for patients with ductal pancreatic adenocarcinoma. Cancer Res 2004;64(10):3533-7 (Pubitemid 38657928)
25. Abe R, Shimizu T, Yamagishi S, et al. Overexpression of pigment epithelium-derived factor decreases angiogenesis and inhibits the growth of human malignant melanoma cells in vivo. Am J Pathol 2004;164(4):1225-32 (Pubitemid 38387789)
26. Garcia M, Fernandez-Garcia NI, Rivas V, et al. Inhibition of xenografted human melanoma growth and prevention of metastasis development by dual antiangiogenic/antitumor activities of pigment epithelium-derived factor. Cancer Res 2004;64(16):5632-42 (Pubitemid 39095559)
27. Yang H, Xu Z, Iuvone PM, Grossniklaus HE. Angiostatin decreases cell migration and vascular endothelium growth factor (VEGF) to pigment epithelium derived factor (PEDF) RNA ratio in vitro and in a murine ocular melanoma model. Mol Vis 2006;12:511-7 (Pubitemid 43778949)
28. Guan M, Pang CP, Yam HF, et al. Inhibition of glioma invasion by overexpression of pigment epithelium-derived factor. Cancer Gene Ther 2004;11(5):325-32 (Pubitemid 38586088)
29. Guan M, Yam HF, Su B, et al. Loss of pigment epithelium derived factor expression in glioma progression. J Clin Pathol 2003;56(4):277-82 (Pubitemid 36459797)
30. Zhang T, Guan M, Xu C, et al. Pigment epithelium-derived factor inhibits glioma cell growth in vitro and in vivo. Life Sci 2007;81(16):1256-63 (Pubitemid 47539504)
31. Quan GM, Ojaimi J, Nadesapillai AP, et al. Resistance of epiphyseal cartilage to invasion by osteosarcoma is likely to be due to expression of antiangiogenic factors. Pathobiology 2002;70(6):361-7 (Pubitemid 36829012)
32. Ek ET, Dass CR, Contreras KG, Choong PF. PEDF-derived synthetic peptides exhibit antitumor activity in an orthotopic model of human osteosarcoma. J Orthop Res 2007;25(12):1671-80 (Pubitemid 350293816)
33. Ek ET, Dass CR, Contreras KG, Choong PF. Inhibition of orthotopic osteosarcoma growth and metastasis by multitargeted antitumor activities of pigment epithelium-derived factor. Clin Exp Metastasis 2007;24(2):93-106 (Pubitemid 46669247)
34. Ek ET, Dass CR, Contreras KG, Choong PF. Pigment epithelium-derived factor overexpression inhibits orthotopic osteosarcoma growth, angiogenesis and metastasis. Cancer Gene Ther 2007;14(7):616-26 (Pubitemid 46912035)
35. Kumar V, Abbas A, Fausto N. Robbins and Cotran pathologic basis of disease. 7th edition. Orlando: Elsevier Saunders; 2005
36. Liu W, Wu Z, Guan M, Lu Y. cDNA microarray analysis of pigment epithelium-derived factor-regulated gene expression profile in prostate carcinoma cells. Int J Urol 2009;16:323-8
37. Hase R, Miyamoto M, Uehara H, et al. Pigment epithelium-derived factor gene therapy inhibits human pancreatic cancer in mice. Clin Cancer Res 2005;11(24 Pt 1):8737-44 (Pubitemid 43005924)
38. Abe R, Fujita Y, Yamagishi S. Angiogenesis and metastasis inhibitors for the treatment of malignant melanoma. Mini Rev Med Chem 2007;7(6):649-61 (Pubitemid 47099184)
39. Cao W, Tombran-Tink J, Chen W, et al. Pigment epithelium-derived factor protects cultured retinal neurons against hydrogen peroxide-induced cell death. J Neurosci Res 1999;57(6):789-800 (Pubitemid 29416109)
40. Yamagishi S, Inagaki Y, Amano S, et al. Pigment epithelium-derived factor protects cultured retinal pericytes from advanced glycation end product-induced injury through its antioxidative properties. Biochem Biophys Res Commun 2002;296(4):877-82
41. Tsuru M, Arima N, Toyozumi Y, Kato S. Pigment epithelium-derived factor as a new diagnostic marker for melanocytic tumors. Kurume Med J 2005;52(3):81-7 (Pubitemid 43251065)
42. Ek ET, Choong PF. The role of high-dose therapy and autologous stem cell transplantation for pediatric bone and soft tissue sarcomas. Expert Rev Anticancer Ther 2006;6(2):225-37 (Pubitemid 44192934)
43. Takenaka K, Yamagishi S, Jinnouchi Y, et al. Pigment epithelium-derived factor (PEDF)-induced apoptosis and inhibition of vascular endothelial growth factor (VEGF) expression in MG63 human osteosarcoma cells. Life Sci 2005;77(25):3231-41 (Pubitemid 41433323)
44. Pillay V, Dass CR, Choong PF. The urokinase plasminogen activator receptor as a gene therapy target for cancer. Trends Biotechnol 2007;25(1):33-9 (Pubitemid 46001467)
45. Dass CR, Nadesapillai AP, Robin D, et al. Downregulation of uPAR confirms link in growth and metastasis of osteosarcoma. Clin Exp Metastasis 2005;22(8):643-52 (Pubitemid 44259525)
46. de Bock CE, Lin Z, Itoh T, et al. Inhibition of urokinase receptor gene expression and cell invasion by anti-uPAR DNAzymes in osteosarcoma cells. FEBS J 2005;272(14):3572-82 (Pubitemid 41021170)
47. Dass CR, Choong PF. uPAR mediates anticancer activity of PEDF. Cancer Biol Ther 2008;7(8):1262-70
48. Kornberg LJ. Focal adhesion kinase and its potential involvement in tumor invasion and metastasis. Head Neck 1998;20(8):745-52 (Pubitemid 28462832)
49. Dass CR, Contreras KG, Dunstan DE, Choong PFM. Chitosan microparticles encapsulating PEDF plasmid demonstrate efficacy in an orthotopic metastatic model of osteosarcoma. Biomaterials 2007;28:3026-33 (Pubitemid 46560874)